Biothera’s drug enhances Avastin’s efficacy

Researchers at the James Graham Brown Cancer Center, University of Louisville, Kentucky, studied the synergistic effects of Imprime PGG in combination with Avastin in a xenograft mouse model where human ovarian cancer cells were implanted into the mice. In the treatment group receiving both Imprime PGG and Avastin, 86% of the mice survived 100 days compared with only 43% in the group receiving Avastin alone.

Daniel Conners, president of Biothera’s Pharmaceutical Group, said: “These results are consistent with our previous research with Imprime PGG and various monoclonal antibodies in numerous cancer indications. We are now working to demonstrate the safety and efficacy of these novel cancer therapies in the clinic.”